Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Inhibition of Cdk Activity

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Targeted Cancer Therapies

Targeted Cancer Therapies

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Oncology pharmacist survey: Understanding task value and professional satisfaction.

Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners·2026

Same author

Time to complete oncology pharmacist tasks: A joint opinion of the Hematology/Oncology Pharmacy Association and American College of Clinical Pharmacy's Hematology/Oncology Practice and Research Network.

Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners·2025

Same author

Dose Modifications in the Management of Chronic Phase Chronic Myeloid Leukemia: Who, What, and When.

Journal of the National Comprehensive Cancer Network : JNCCN·2024

Same author

Development of oral oncolytic nonadherence estimator (ORACLE): A pretreatment nonadherence risk assessment for oral oncolytics.

Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners·2023

Same author

Anxiety exacerbation in a patient with chronic myeloid leukemia receiving dasatinib and venlafaxine.

Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners·2023

Same author

Oral Antineoplastics in Acute Myeloid Leukemia: A Comprehensive Review.

Clinical lymphoma, myeloma & leukemia·2022

Search research articles

Related Experiment Video

Updated: Mar 14, 2026

A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells

A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells

Published on: March 28, 2021

Cobimetinib.

Jessie Signorelli¹, Arpita Shah Gandhi²

¹1 Nebraska Medical Center, Omaha, NE, USA.

The Annals of Pharmacotherapy

|October 5, 2016

Summary

Cobimetinib combined with vemurafenib offers an alternative treatment for melanoma patients with BRAF mutations. This BRAF/MEK inhibitor therapy demonstrated improved progression-free survival in clinical trials.

Area of Science:

Oncology
Pharmacology

Background:

Melanoma with BRAFV600 mutations presents a target for targeted therapies.
Cobimetinib is a MEK inhibitor approved for use with vemurafenib.

Purpose of the Study:

To review and summarize data on cobimetinib's efficacy and safety.
To assess cobimetinib in combination with vemurafenib for melanoma treatment.

Main Methods:

Literature search of PubMed (2000-2016) for cobimetinib, MEK inhibitor, and melanoma.
Prioritization of human studies in English, focusing on melanoma trials.

Main Results:

Cobimetinib, a MEK1/MEK2 inhibitor, combined with vemurafenib showed a 68% objective response rate.
Median progression-free survival was 9.9 months; common adverse events included diarrhea and rash.

Keywords:

cancer drug development and approval oncology pharmacodynamics pharmacokinetics

More Related Videos

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries

Published on: January 22, 2019

Related Experiment Videos

Last Updated: Mar 14, 2026

A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells

A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells

Published on: March 28, 2021

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries

Published on: January 22, 2019

The combination therapy is approved by the FDA for specific melanoma mutations.

Conclusions:

Cobimetinib plus vemurafenib is an alternative BRAF/MEK inhibitor therapy for unresectable or metastatic melanoma.
The role of cobimetinib in melanoma treatment is expected to grow with ongoing research.